GENETIC THERAPY COULD RECEIVE UP TO $18 MIL. FROM SANDOZ FOR HS-tk
Executive Summary
GENETIC THERAPY COULD RECEIVE UP TO $18 MIL. FROM SANDOZ FOR HS-tk technology for cancer treatment, Genetic Therapy, Inc, announced June 15, Sandoz will make an upfront payment "exceeding" $6 mil. and milestone payments of up to $12 mil. under a joint product development and marketing agreement, with the possibility of subsequent HS-tk (herpes simplex thymidine kinase) products "carrying additional upfront and milestone payments if developed under the agreement," the firm noted.